The Heart -- Adding an ACE inhibitor to standard medical therapy improves outcomes in patients with ischemic heart disease and preserved left ventricular function, a new review concludes. But the evidence that adding angiotensin-receptor blockers (ARBs) to treatment in such patients is of any benefit is much weaker, the study finds. Nor is there any support for using a combination of ACE inhibitor and ARB in these individuals.
